Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06434597
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-05-23
Brief Title:
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positiveMutated Biliary Tract OR Colorectal Cancer Patients
Sponsor:
Shanghai Pharmaceuticals Holding Co Ltd
Organization:
Shanghai Pharmaceuticals Holding Co Ltd
Study Overview
Official Title:
A Multicenter Open Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positiveMutated Biliary Tract OR Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positivemutated biliary tract OR colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None